A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Neoplasms, Breast Clinical Trial

Official title:

An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00849329
• Other study ID #: 109275
• Status: Completed
• Phase: Phase 1
• First received: February 12, 2009
• Last updated: November 10, 2017
• Start date: March 10, 2009
• Est. completion date: November 24, 2009

Study information

• Verified date: November 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: November 24, 2009
• Est. primary completion date: November 24, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Metastatic, histologically confirmed breast cancer that overexpresses ErbB2 (3+ by IHC, FISH, or CISH positive).

• 18 years to 65 years of age.

• Is male or female (of non childbearing potential or willing to use contraception as specified in the protocol).

• Is able to swallow and retain oral medication.

• ECOG performance status 0 to 2.

• Provided written informed consent.

• Adequate bone marrow function (as specified in the protocol).

• Calculated creatinine clearance (CrCl) greater than or equal to 50 ml/min based on Cockcroft and Gault.

• Total bilirubin less than or equal to 1.5 X upper limit of normal of institutional values.

• Alanine transaminase (ALT) less than or equal to 3 times the upper limit of the institutional values or less than or equal to 5 times ULN with documented liver metastases

• Has a left ventricular ejection fraction (LVEF) within the normal institutional range based on ECHO or MUGA.

• Life expectancy of greater than or equal to 12 weeks

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

• Pregnant or lactating woman.

• Has malabsorption syndrome, a disease affecting gastrointestinal function, or resection of the stomach or small bowel.

• Has current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)

• Has evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease. Subjects with brain metastases treated by surgery and/or radiotherapy are eligible if neurologically stable and do not require steroids or anticonvulsants.

• Is considered medically unfit for the study by the investigator.

• Has a known immediate or delayed benzimidazole hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product such as gefitinib [Iressa] and erlotinib [Tarceva].

• Has received treatment with any investigational drug in the previous four weeks. (with the exception of lapatinib).

• Has received chemotherapy, immunotherapy, biologic therapy or hormonal therapy for the treatment of cancer within the past 14 days, with the exception of mitomycin C which is restricted for the past six weeks, and lapatinib. Subjects receiving lapatinib prior to study entry are eligible to participate in the study.

• Is receiving any prohibited medication within the timeframe indicated on the prohibited medication list in the protocol.

• Has physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

• Has inadequate venous access for protocol-related blood draws.

• Clinically significant electrocardiogram abnormality.

• History of sensitivity to heparin or heparin-induced thrombocytopenia.

• Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or kumquats, pummelos, exotic citrus fruit (i.e. star fruit, bitter melon), grapefruit hybrids or fruit juices from seven days prior to the first dose of study medication.

Related Conditions & MeSH terms

• Breast Neoplasms
• Neoplasms, Breast

Intervention

Drug:
• lapatinib
1250mg lapatinib
• lapatinib plus esomeprazole
1250mg lapatinib plus esomeprazole 40mg

Locations

Country	Name	City	State
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Songpa-gu, Seoul
Spain	GSK Investigational Site	Hospitalet de Llobregat (Barcelona)
United States	GSK Investigational Site	Greenville	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Korea, Republic of,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the concentration versus time curve, minimum observed concentration, maximum observed concentration, time at which it occurs, and lag time in the appearance of measurable plasma concentrations of lapatinb		Continue until disease progression or withdrawal consent
Secondary	Safety and tolerability assessments including evaluation of adverse events and changes in laboratory values, and vital signs.		Continue until disease progression or withdrawal consent

External Links

•   Results for study 109275 can be found on the GSK Clinical Study Register.